Icomb 10 Mg/5 Mg

Ramipril, the active ingredient in Icomb 10 Mg/5 Mg, is an ACE inhibitor presented as a 10 mg/5 mg tablet for oral use. It lowers blood pressure by inhibiting the renin‑angiotensin system and is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Icomb 10 Mg/5 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this antihypertensive combination.

Icomb 10 Mg/5 Mg is used to manage hypertension, a condition involving elevated arterial pressure.

Essential hypertension: improves blood pressure control in patients with primary hypertension. Secondary hypertension: assists in lowering blood pressure when hypertension is caused by another underlying disorder. Hypertension with cardiovascular risk: provides combined ACE inhibition and calcium‑channel blockade to reduce overall cardiovascular strain.

Common Side Effects: - Cough - Dizziness or light‑headedness - Peripheral edema - Flushing or warmth sensation - Headache - Fatigue

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension - Hepatic enzyme elevation - Myocardial infarction - Cardiac arrhythmias - Neutropenia or other blood dyscrasias

Before initiating therapy, consider the following precautions.

Monitor blood pressure regularly: ensure therapeutic effect and avoid excessive lowering. Assess renal function: dose adjustment may be needed in renal impairment. Check electrolyte levels: especially potassium, due to ACE‑inhibitor effect. Caution in heart failure patients: monitor for fluid retention. Avoid in patients with known hypersensitivity to ramipril, amlodipine, or any excipients. Store at ambient temperature: keep in the original pack, protect from moisture.

Icomb 10 Mg/5 Mg may interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Aliskiren (dual renin‑angiotensin blockade) - Potassium‑sparing diuretics (risk of hyperkalaemia) - NSAIDs (may blunt antihypertensive effect and affect renal function) - High‑dose simvastatin (increased risk of myopathy) - Strong CYP3A4 inhibitors (e.g., itraconazole) affecting amlodipine levels

Moderate Interactions (Monitor Closely): - Thiazide diuretics (additive blood pressure lowering) - Beta‑blockers (enhanced hypotensive effect) - Lithium (increased lithium levels) - Rifampin (induces metabolism, may reduce efficacy) - Digoxin (monitor serum levels due to possible changes in clearance)